Blood Cancer disease

A rare variant of blood cancer is known as the Wisconsin Syndrome. With the most common variations, heart and skeletal cancer is the main cause of blood cancer. In the Wisconsin Syndrome, the structural alteration takes the form of mutation in the Neuronal Disease Severity Code or NDSSC.

That mutation, when present with microglia and interleukin-6A, culminates in a form of abnormal blood cell growth (Weil, 2018). These abnormal conditions that cause blood cancer commonly result from prolonged exposure to toxic substances. During the inflammation caused by immune syndrome, the toxic steroids released in the microglia increase M-cells’ immune cells to create an overactive system (Dahlgren, 2015). This extreme growth of M-cells at the expense of T-cells leads to damage of T-cells resulting in blood cancer.

The gene mutation in Wisconsin Syndrome occurs in 2% of patients, often resulting in bone marrow failure. Therefore, bone marrow is found to be crucial for immune responses against more than 450 diseases. Most patients with Wisconsin Syndrome experience bone marrow damage resulting in thickening of the bone marrow. The bone marrow’s cells become prone to malfunction to an extent that they turn into malignancy cells.

Given the difference between the millions of bone marrow cells inherited through genetic inheritance and the bare bone marrow of a single patient, it is difficult to predict the predictive nature of the Wisconsin Syndrome’s prognosis or impact on a particular population (Dahlgren, 2015). In addition, cancer usually occurs in very young adults who have a strong genetic susceptibility (Weil, 2018). Therefore, in any given population, medical experts use statistical analysis of genetic ancestry to detect patterns and predict future outcomes (Dahlgren, 2015).

Comparing Wisconsin Syndrome to other types of blood cancer

There are many different types of blood cancer. The type of cancer-based on genetic ancestry determines how much genetic mutation will occur in the cellular cells. Treatments to people diagnosed with Wisconsin Syndrome depend on their genetic predisposition to it.

Most forms of blood cancer have not been rigorously studied yet but they have shown to be severe and costly. For that reason, blood cancers are underdiagnosed by laboratory tests, especially due to their complexity and low prognosis. Although all forms of blood cancer have differing characteristics, they all have one common characteristic, that, uncontrolled malignancy development leads to bone marrow dysfunction resulting in susceptibility to harsh diseases such as osteoporosis. Osteoporosis can lead to bone pain, bone fractures, cardiac failure, and even cardiovascular death. Therefore, because of these bad prognoses and potential implications for limb loss, researchers do not explore the cause of Wisconsin Syndrome.

There are two major types of Wisconsin Syndrome, chronic disease development syndrome and metastatic fatality syndrome (Weil, 2018). Chronic disease development syndrome is considered to be worse than both autoimmune diseases, autoimmune liver disease, and chemotherapy. The term “Wisconsin Syndrome” also incorporates chronic kidney disease, rheumatoid arthritis, and rheumatoid arthritis as well as malignant neoplasms.

M-cell biology is under examination to investigate the cause of Wisconsin Syndrome (Dahlgren, 2015). However, for now, cancer chemotherapy treatment, anti-viral drugs, and immune-suppressing drugs provide the best treatment for treating Wisconsin Syndrome. For cancer patients who were previously treated for chronic liver disease, a monoclonal antibody and biopsy are provided during the current treatment. Therefore, there is an opportunity to estimate and prevent diseases in the future.